Literature DB >> 28180242

11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension.

Lama Ghazi1, Tanja Dudenbostel1, Maria El Hachem1, Mohammed Siddiqui1, Chee Paul Lin2, Suzanne Oparil1, David A Calhoun1.   

Abstract

BACKGROUND AND
OBJECTIVE: Decreased renal 11-beta dehydrogenase type 2 (11β-HSD2) activity, as reflected by an increased urinary free cortisol to cortisone ratio (UFF/UFE), is associated with having hypertension (HTN). The current study was conducted to determine if reduced 11β-HSD2 activity is also associated with having resistant HTN.
METHOD: We evaluated 55 consecutive patients with RHTN, defined as blood pressure (BP) ≥140/90 mm Hg despite using ≥3 antihypertensive medications including a diuretic, and 38 patients whose BP was controlled on ≤3 medications to serve as a non-RHTN comparator group. All patients underwent biochemical evaluation, including measurement of 24-hour urinary UFF/UFE.
RESULTS: The 2 study groups had similar demographic characteristics. Systolic, diastolic BP, and number of antihypertensive medications were greater in patients with uncontrolled RHTN vs. the control group (167.5 ± 28.2/91.2 ± 18.8 vs. 126.6 ± 11.4/77.8 ± 8.65 mm Hg and 4.31 ± 1.23 vs. 2.74 ± 0.6, respectively). The 24-hour UFF was 13.6 ± 11.8 vs. 14.3 ± 10.7 µg/24 h and UFE was 64.9 ± 36.3 vs. 76.1 ± 44 µg/24 h such that the UFF/UFE was 0.22 ± 0.16 vs. 0.19 ± 0.09 in RHTN vs. the control group. This ratio was not associated to age, race, gender, and body mass index.
CONCLUSION: An elevated UFF/UFE was not present in this large cohort of patients with uncontrolled RHTN. This suggests that reduced conversion of cortisol to cortisone does not contribute to the development of RHTN. © American Journal of Hypertension, Ltd 2017. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  11-beta dehydrogenase type 2; blood pressure; cortisol/ cortisone ratio; hypertension; resistant hypertension.

Mesh:

Substances:

Year:  2017        PMID: 28180242      PMCID: PMC5861581          DOI: 10.1093/ajh/hpx002

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  38 in total

1.  Simultaneous measurement of aldosterone and cortisol by high-performance liquid chromatography-tandem mass spectrometry: application to dehydration-rehydration studies.

Authors:  Paul J Taylor; Simon P van Rosendal; Jeff S Coombes; Richard D Gordon; Michael Stowasser
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-03-23       Impact factor: 3.205

Review 2.  11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.

Authors:  Nicole Draper; Paul M Stewart
Journal:  J Endocrinol       Date:  2005-08       Impact factor: 4.286

3.  Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11 beta-hydroxysteroid dehydrogenase in vivo.

Authors:  R Best; B R Walker
Journal:  Clin Endocrinol (Oxf)       Date:  1997-08       Impact factor: 3.478

4.  Sodium status, corticosteroid metabolism and blood pressure in normal human subjects and in a patient with abnormal salt appetite.

Authors:  M C Ingram; A M Wallace; A Collier; R Fraser; J M Connell
Journal:  Clin Exp Pharmacol Physiol       Date:  1996-05       Impact factor: 2.557

5.  Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man.

Authors:  M Palermo; C H Shackleton; F Mantero; P M Stewart
Journal:  Clin Endocrinol (Oxf)       Date:  1996-11       Impact factor: 3.478

Review 6.  A genetic defect resulting in mild low-renin hypertension.

Authors:  R C Wilson; S Dave-Sharma; J Q Wei; V R Obeyesekere; K Li; P Ferrari; Z S Krozowski; C H Shackleton; L Bradlow; T Wiens; M I New
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 7.  Hypertension and the cortisol-cortisone shuttle.

Authors:  Marcus Quinkler; Paul M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

8.  Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension.

Authors:  A Soro; M C Ingram; G Tonolo; N Glorioso; R Fraser
Journal:  Hypertension       Date:  1995-01       Impact factor: 10.190

9.  Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension.

Authors:  B R Walker; P M Stewart; C H Shackleton; P L Padfield; C R Edwards
Journal:  Clin Endocrinol (Oxf)       Date:  1993-08       Impact factor: 3.478

10.  Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.

Authors:  T Mune; F M Rogerson; H Nikkilä; A K Agarwal; P C White
Journal:  Nat Genet       Date:  1995-08       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.